{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-016400","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.291944+00:00","generated_at":"2026-05-15T16:32:17.740065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Skye reports Q4 loss $14.4M, cash $25.7M; initiates higher-dose CBeyond study after 22.3% weight loss at 52 weeks","bullets":["Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.","Interim 52-week data: nimacimab+semaglutide achieved 22.3% mean weight loss; no plateau observed.","Initiated CBeyond Expansion Study: higher doses (400 mg and 600 mg IV) vs placebo; topline Q4 2026.","Weight regain during 13-week off-treatment: combo cohort regained 17.8% vs 37.3% for semaglutide alone.","FDA Type C meeting completed; feedback informing Phase 2b design including potential add-on with incretin."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-016400","json":"https://secwatch.observer/filing/0001628280-26-016400.json","markdown":"https://secwatch.observer/filing/0001628280-26-016400.md","text":"https://secwatch.observer/filing/0001628280-26-016400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/0001628280-26-016400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/skye-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:32:17.740065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}